HealthCentral.com

Drug Library

HealthCentral Drug Library

Neurontin - Indications & Dosage

[Gabapentin]




INDICATIONS AND USAGE

Postherpetic Neuralgia
Neurontin (gabapentin) is indicated for the management of postherpetic neuralgia in adults.

Epilepsy
Neurontin (gabapentin) is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.

Neurontin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 ? 12 years.

DOSAGE AND ADMlNlSTRATION

Neurontin is given orally with or without food. If Neurontin dose is reduced, discontinued or substituted with an alternative medication, this should be done gradually over a minimum of 1 week.

Postherpetic Neuralgia
In adults with postherpetic neuralgia, Neurontin therapy may be initiated as a single 300-mg dose on Day 1, 600 mg/ day on Day 2 (divided BID), and 900 mg/ day on Day 3 (divided TID).

The dose can subsequently be titrated up as needed for pain relief to a daily dose of 1800 mg (divided TID). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/ day to 3600 mg/ day with comparable effects across the dose range. Additional benefit of using doses greater than 1800 mg/ day was not demonstrated.


Epilepsy

Neurontin is recommended for add-on therapy in patients 3 years of age and older. Effectiveness in pediatric patients below the age of 3 years has not been established.

Patients >12 years of age:

The effective dose of Neurontin is 900 to 1800 mg/ day and given in divided doses (three times a day) using 300 or 400 mg capsules, or 600 or 800 mg tablets. The starting dose is 300 mg three times a day. If necessary, the dose may be increased using 300 or 400 mg capsules, or 600 or 800 mg tablets three times a day up to 1800 mg/ day. Dosages up to 2400 mg/ day have been well tolerated in long-term clinical studies. Doses of 3600 mg/ day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. The maximum time between doses in the TID schedule should not exceed 12 hours.